52
Views
6
CrossRef citations to date
0
Altmetric
Original Research

A comparative study of 43 patients with mirror-like intracranial aneurysms: risk factors, treatment, and prognosis

, , , , &
Pages 2231-2237 | Published online: 19 Nov 2014

Figures & data

Table 1 Demographic characteristics according to the type of intracranial aneurysm

Figure 1 Relative prevalence of risk factors by age. (A) In patients with MirAn. (B) In nMirAn patients.

Note: Smoking refers to cigarette smoking.
Abbreviations: HBP, high blood pressure; MirAn, mirror-like intracranial aneurysms; nMirAn, non-mirror-like multiple aneurysms; NRF, no known extrinsic risk factors.
Figure 1 Relative prevalence of risk factors by age. (A) In patients with MirAn. (B) In nMirAn patients.

Table 2 Hunt and Hess grade and aneurysm sites in patients with SAH

Figure 2 DSA images of both the left and right internal carotid arteries before clipping. DSA suggests that the aneurysms arise from the branches of the bilateral middle cerebral artery (indicated by arrow).

Notes: (A) Right internal carotid artery (normal position); (B) right internal carotid artery (lateral position); (C) left internal carotid artery (normal position); (D) left internal carotid artery (lateral position).
Abbreviation: DSA, digital subtraction angiography.
Figure 2 DSA images of both the left and right internal carotid arteries before clipping. DSA suggests that the aneurysms arise from the branches of the bilateral middle cerebral artery (indicated by arrow).

Figure 3 DSA images of the left and right internal carotid arteries after clipping. Both aneurysms from the bilateral middle cerebral artery branches are completely occluded (normal position, indicated by the arrow).

Notes: (A) Left aneurysms; (B) right aneurysms.
Abbreviation: DSA, digital subtraction angiography.
Figure 3 DSA images of the left and right internal carotid arteries after clipping. Both aneurysms from the bilateral middle cerebral artery branches are completely occluded (normal position, indicated by the arrow).

Table 3 Treatment and follow-up for the patients with MirAn